HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Abstract
1. Systemic infusions of urocortin 1 produce a decrease in mean arterial pressure. This effect may be mediated by a direct action on novel corticotropin-releasing factor type 2 (CRF(2)) receptors predicted to be expressed in blood vessels and the heart. Our objectives were to determine the presence of CRF(2) receptors in the human cardiovascular system using the selective radioligand [(125)I]antisauvagine 30. We also investigated the potential functional roles of novel CRF(2) ligands in the regulation of vascular tone in human arteries in vitro. 2. Radioligand binding techniques were used to characterise the CRF(2) receptor. [(125)I]antisauvagine 30 bound specifically, saturably, reversibly and with high affinity to CRF(2) receptors in human left ventricle (K(D) 0.21+/-0.03 nm, B(MAX) 0.80+/-0.18 fmol mg(-1) protein), and no change in receptor density or affinity was observed in the dilated cardiomyopathy group. 3. Autoradiographical studies revealed highly localised binding of [(125)I]antisauvagine 30 to intramyocardial blood vessels. Binding sites were also detected in the myocardium and in the medial layer of internal mammary arteries. 4. In endothelium-denuded human internal mammary artery in vitro, all peptides tested produced a potent and sustained vasodilator response reversing endothelin-1-induced constrictions (10 nm) (urocortin 1: pD(2) 8.39+/-0.32, E(MAX) 46+/-7.7%; urocortin 2: pD(2) 8.27+/-0.17, E(MAX) 60+/-8.5%; urocortin 3: pD(2) 8.61+/-0.25, E(MAX) 61+/-7.2%; CRF: pD(2) 8.28+/-0.27, E(MAX): 40+/-10%). 5. We have demonstrated the presence of CRF(2) receptors in the human cardiovascular system and a direct, endothelium-independent vasodilator action of urocortins 2 and 3, which may counter-balance the centrally mediated pressor effects of CRF and urocortin 1.
AuthorsKatherine E Wiley, Anthony P Davenport
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 143 Issue 4 Pg. 508-14 (Oct 2004) ISSN: 0007-1188 [Print] England
PMID15381637 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CRF receptor type 2
  • Ligands
  • Receptors, Corticotropin-Releasing Hormone
  • Urocortins
  • Vasodilator Agents
  • Corticotropin-Releasing Hormone
Topics
  • Adolescent
  • Adult
  • Aged
  • Cardiovascular System (drug effects, metabolism)
  • Corticotropin-Releasing Hormone (metabolism, pharmacology)
  • Dose-Response Relationship, Drug
  • Female
  • Gene Expression Regulation (drug effects, physiology)
  • Humans
  • Ligands
  • Male
  • Mammary Arteries (drug effects, metabolism)
  • Middle Aged
  • Myocardium (metabolism)
  • Protein Binding (drug effects, physiology)
  • Receptors, Corticotropin-Releasing Hormone (agonists, biosynthesis)
  • Urocortins
  • Vasodilator Agents (metabolism, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: